{"eventGroups":[{"deathsNumAffected":1,"deathsNumAtRisk":1,"description":"Patients receive rituximab IV on day 1. Within 7 to 9 days, patients receive rituximab IV and yttrium Y 90 ibritumomab tiuxetan IV in the absence of disease progression or unacceptable toxicity.\n\nrituximab: Given IV\n\nyttrium Y 90 ibritumomab tiuxetan: Given IV","id":"EG000","otherNumAffected":0,"otherNumAtRisk":1,"seriousNumAffected":0,"seriousNumAtRisk":1,"title":"Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan"}],"frequencyThreshold":"5"}